2 years ago

Metrion Biosciences Secures £3.7 Million for Ion Channel Drug Discovery Expansion

  • Metrion Biosciences, a Cambridge, UK-based ion channel CRO and drug discovery company, raised £3.7 million in funding led by Maven Capital Partners, alongside Gresham House Ventures

  • The company intends to use the funds to further expand its laboratories in Cambridge, UK, invest in specialist equipment and enhance global marketing activities

  • Metrion Biosciences specializes in providing a range of ion channel drug discovery services for its customers, including compound screening assays, detailed characterization of lead compounds in human cells and native tissue, as well as confirmation of efficacy in stem cell and other phenotypic models.

      • ProblemHealthcare

      "making ion channel drug discovery services more accessible and tailored to individual client needs"

      Solution

      "providing a dedicated, flexible ion channel drug discovery service that includes compound screening assays, detailed characterization of lead compounds, and confirmation of efficacy in various models"

      Covered on